Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer

NCT01574937 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT01574937
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01574937 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Dose Finding Clinical Trial of Cabozantinib (XL 184) Administered in Combination With Abiraterone in Castration Resistant Prostate Cancer
Lead sponsor
Dana-Farber Cancer Institute
Phase
Phase 1
Overall status
Completed
Start date
April 3, 2012
Completion date
July 1, 2021
Enrollment
27 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer